Episode
Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms
- Podcast
- HCPLive Podcasts
- Published
- May 28, 2026
- Duration seconds
- 1500
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8909059
Actions
POST https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/joint-ventures-nipocalimab-advances-and-a-deucravacitinib-decision-looms/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-nipocalimab-advances-and-a-deucravacitinib-decision-looms.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Joint Ventures , hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MBBS, a consultant rheumatologist at Freeman Hospital, dive into 2 emerging therapeutic strategies with the potential to reshape care for systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA): Fc receptor blockade with nipocalimab and tyrosine kinase 2 (TYK2) inhibition with deucravacitinib, distinct pathways united by a shared goal of greater precision in immune modulation.